Normunity

About Normunity

Normunity is a biotech company focused on developing novel anti-cancer therapies that target the interface between the immune system and tumors. Their mission is to uncover ideal cancer drug targets and create medicines that address tumor-specific immunosuppression and immune surveillance circumvention.

Products & Services

Therapeutic Antibodies:Anti-cancer medicines targeting novel proteins identified through proprietary discovery processes.

Bispecific Antibodies:Biologic medicines designed to leverage tumor-specific characteristics for cancer treatment.

Payload-Carrying Biologics:Innovative biologics aimed at addressing untapped mechanisms in tumor growth and immune evasion.

Specialties

Anti-cancer therapy development Immune system and tumor interface research Therapeutic antibodies Bispecific antibodies Payload-carrying biologics Tumor-specific immunosuppression targeting

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 75000000 MR: - FA: 75 million FAN: 75000000	D: 2025-01-13 FD: 2025-01-13	11 investors

Series B Latest

2025-01-13

$75.0M

11 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Rachel Humphrey

Founding Chief Executive Officer

D

Darlene Deptula-Hicks

Interim Chief Financial Officer

W

William LaRochelle

Chief Scientific Officer

M

Melinda Merchant

Chief Medical Officer

F

François Gaudet

Senior Scientific Advisor

K

Kristin Robbins

VP, Program & Portfolio Management

View 20 more team members with Pro

Unlock Full Team Directory

Recent News

Normunity Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised